Sanofi completes acquisition of Vigil Neuroscience for $8.00/sh + CVR

Vigil Neuroscience, Inc.

Merger closed Aug 5, 2025; each share of VIGL converted to $8.00 cash plus one CVR.
CVR entitles holder to $2.00 per CVR upon first commercial sale of VG-3927 for Alzheimer's.
Stockholders voted 35,191,885 for, 9,521 against, 133,827 abstain to adopt merger.
All directors and officers resigned; replaced by designees of Sanofi.
VIGL common stock trading halted; delisting and deregistration initiated.

item 2.01item 3.01item 3.03item 5.01item 5.02item 5.03item 5.07item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.